Sara K Quinney

List of Publications by Year
in descending order

90 papers	1,886 citations	331642 21 h-index	289230 40 g-index
94 all docs	94 docs citations	94 times ranked	2569 citing authors

#	Article	IF	Citations
1	Multiscale Model of Antiviral Timing, Potency, and Heterogeneity Effects on an Epithelial Tissue Patch Infected by SARS-CoV-2. Viruses, 2022, 14, 605.	3.3	8
2	Are Newborn Outcomes Different for Term Babies Who Were Exposed to Antenatal Corticosteroids?. Obstetrical and Gynecological Survey, 2022, 77, 251-252.	0.4	0
3	Pharmacokinetics of Vaginal vs Buccal Misoprostol for Labor Induction at Term. Clinical and Translational Science, 2022, , .	3.1	2
4	Prophylactic evaluation of verubecestat on diseaseâ€•and symptomâ€•modifying effects in 5XFAD mice. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	3.7	5
5	PhenoDEF: a corpus for annotating sentences with information of phenotype definitions in biomedical literature. Journal of Biomedical Semantics, 2022, 13, .	1.6	3
6	Stereoselective Analysis of Methadone and EDDP in Laboring Women and Neonates in Plasma and Dried Blood Spots and Association with Neonatal Abstinence Syndrome. American Journal of Perinatology, 2021, 38, 968-975.	1.4	7
7	Recruitment strategies and design considerations in a trial of resistance training to prevent dose-limiting toxicities in colon cancer patients undergoing chemotherapy. Contemporary Clinical Trials, 2021, 101, 106242.	1.8	13
8	A Novel Perioperative Multidose Methadone-Based Multimodal Analgesic Strategy in Children Achieved Safe and Low Analgesic Blood Methadone Levels Enabling Opioid-Sparing Sustained Analgesia With Minimal Adverse Effects. Anesthesia and Analgesia, 2021, 133, 327-337.	2.2	12
9	Are newborn outcomes different for term babies who were exposed to antenatal corticosteroids?. American Journal of Obstetrics and Gynecology, 2021, 225, 536.e1-536.e7.	1.3	15
10	Do maternal demographics and prenatal history impact the efficacy of betamethasone therapy for threatened preterm labor?. BMC Pregnancy and Childbirth, 2021, 21, 442.	2.4	1
11	Novel associations between CYP2B6 polymorphisms, perioperative methadone metabolism and clinical outcomes in children. Pharmacogenomics, 2021, 22, 591-602.	1.3	4
12	Physiologically based pharmacokinetic modelling in pregnancy: Model reproducibility and external validation. British Journal of Clinical Pharmacology, 2021, , .	2.4	6
13	Pharmacokinetic modeling of R and Sâ€•Methadone and their metabolites to study the effects of various covariates in postâ€•operative children. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1183-1194.	2.5	3
14	Comparing Newborn Outcomes After Prenatal Exposure to Individual Antidepressants: a retrospective cohort study. Pharmacotherapy, 2021, 41, 907-914.	2.6	8
15	Patients with Mood Disorders Require Higher Doses of Buprenorphine for Management of Opioid Use Disorder but Have No Increased Risk of Neonatal Abstinence Syndrome. North American Proceedings in Gynecology & Obstetrics, 2021, 1, .	0.0	0
16	The Impact of Hepatitis C Virus Infection on Buprenorphine Dose in Pregnancy. American Journal of Perinatology, 2020, 37, 073-078.	1.4	1
17	Translational Knowledge Discovery Between Drug Interactions and Pharmacogenetics. Clinical Pharmacology and Therapeutics, 2020, 107, 886-902.	4.7	11
18	Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus. Clinical Pharmacology and Therapeutics, 2020, 107, 1362-1372.	4.7	8

#	Article	IF	Citations
19	Pharmacodynamics of Metformin in Pregnant Women With Gestational Diabetes Mellitus and Nonpregnant Women With Type 2 Diabetes Mellitus. Journal of Clinical Pharmacology, 2020, 60, 540-549.	2.0	4
20	Pharmacokinetics of Basiliximab for the Prevention of Graftâ€versusâ€Host Disease in Patients Undergoing Hematopoietic Cell Transplantation with Minimalâ€Intensity Cyclophosphamide and Fludarabine. Pharmacotherapy, 2020, 40, 26-32.	2.6	3
21	Improving natural product research translation: From source to clinical trial. FASEB Journal, 2020, 34, 41-65.	0.5	45
22	396: The impact of centeringpregnancy group prenatal care on breastfeeding rates in buprenorphine exposed pregnancies. American Journal of Obstetrics and Gynecology, 2020, 222, S262.	1.3	1
23	Pharmacogenomics of methadone: a narrative review of the literature. Pharmacogenomics, 2020, 21, 871-887.	1.3	14
24	A pharmacometricianâ€™s role in enhancing medication use in pregnancy and lactation. Journal of Pharmacokinetics and Pharmacodynamics, 2020, 47, 267-269.	1.8	3
25	Inquiry into the short- and long-term effects of Roux-en-Y gastric bypass on the glomerular filtration rate. Renal Failure, 2020, 42, 624-628.	2.1	5
26	Pharmacokinetic, pharmacodynamic and transcriptomic analyses of verubecestat treatment in 5XFAD mice. Alzheimer's and Dementia, 2020, 16, e041491.	0.8	0
27	Effects of Pregnancy on the Pharmacokinetics of Metformin. Drug Metabolism and Disposition, 2020, 48, 264-271.	3.3	31
28	Mining and visualizing high-order directional drug interaction effects using the FAERS database. BMC Medical Informatics and Decision Making, 2020, 20, 50.	3.0	11
29	Improving preclinical to clinical translation in Alzheimer's disease research. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12038.	3.7	20
30	Rate of Cervical Change During Ripening in Nulliparous Women Using Vaginal or Buccal Misoprostol [38J]. Obstetrics and Gynecology, 2020, 135, 113s.	2.4	0
31	Impact of Group Prenatal Care on Neonatal Outcomes in Women With Opioid Use Disorder [17O]. Obstetrics and Gynecology, 2020, 135, 161S.	2.4	0
32	A comparison of vaginal versus buccal misoprostol for cervical ripening in women for labor induction at term (the IMPROVE trial): a triple-masked randomized controlled trial. American Journal of Obstetrics and Gynecology, 2019, 221, 259.e1-259.e16.	1.3	22
33	The Cancer Drug Fraction of Metabolism Database. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 511-519.	2.5	7
34	Controversies in antenatal corticosteroids. Seminars in Fetal and Neonatal Medicine, 2019, 24, 182-188.	2.3	24
35	Opportunities and Challenges of Using Big Data to Detect Drugâ€Drug Interaction Risk. Clinical Pharmacology and Therapeutics, 2019, 106, 72-74.	4.7	6
36	346: The impact of breastfeeding on neonatal abstinence syndrome in buprenorhpine exposed neonates. American Journal of Obstetrics and Gynecology, 2019, 220, S241.	1.3	1

#	Article	IF	Citations
37	649: Impact of hepatitis C virus infection on buprenorphine dose in pregnancy. American Journal of Obstetrics and Gynecology, 2019, 220, S431.	1.3	0
38	Buccal versus Vaginal Misoprostol for Term Induction of Labor: A Retrospective Cohort Study. American Journal of Perinatology, 2019, 36, 765-772.	1.4	7
39	Mining Directional Drug Interaction Effects on Myopathy Using the FAERS Database. IEEE Journal of Biomedical and Health Informatics, 2019, 23, 2156-2163.	6.3	11
40	Translational Systems Pharmacology Studies in Pregnant Women. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 69-81.	2.5	8
41	Translational Biomedical Informatics and Pharmacometrics Approaches in the Drug Interactions Research. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 90-102.	2.5	15
42	Translational Highâ€Dimensional Drug Interaction Discovery and Validation Using Health Record Databases and Pharmacokinetics Models. Clinical Pharmacology and Therapeutics, 2018, 103, 287-295.	4.7	22
43	Mixture drugâ€count response model for the highâ€dimensional drug combinatory effect on myopathy. Statistics in Medicine, 2018, 37, 673-686.	1.6	9
44	P2â€045: THE MODELâ€AD CONSORTIUM PRECLINICAL TESTING PIPELINE: PHARMACOKINETICS AND PHARMACODYNAMICS OF PROPHYLACTIC TREATMENT WITH LEVETIRACETAM IN THE 5XFAD MOUSE MODEL OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P684.	0.8	0
45	Analyzing Patterns of Literature-Based Phenotyping Definitions for Text Mining Applications. , 2018, , .		2
46	DrugMetab: An Integrated Machine Learning and Lexicon Mapping Named Entity Recognition Method for Drug Metabolite. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 709-717.	2.5	3
47	Threeâ€Component Mixture Modelâ€Based Adverse Drug Event Signal Detection for the Adverse Event Reporting System. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 499-506.	2.5	7
48	Characterization of Maternal and Fetal CYP3A-Mediated Progesterone Metabolism. Fetal and Pediatric Pathology, 2017, 36, 400-411.	0.7	12
49	Survey of Provider Preferences Regarding the Route of Misoprostol for Induction of Labor at Term. AJP Reports, 2017, 07, e158-e162.	0.7	4
50	Buccal Versus Vaginal Misoprostol for Term Induction of Labor. Obstetrics and Gynecology, 2016, 127, 96S.	2.4	1
51	Effect of Gastric Fluid Volume on the In Vitro Dissolution and In Vivo Absorption of BCS Class II Drugs: a Case Study with Nifedipine. AAPS Journal, 2016, 18, 981-988.	4.4	19
52	268: Respiratory distress syndrome in preterm neonates isÂassociated with betamethasone clearance. American Journal of Obstetrics and Gynecology, 2016, 214, S157.	1.3	0
53	Identification and Mechanistic Investigation of Drugâ€“Drug Interactions Associated With Myopathy: A Translational Approach. Clinical Pharmacology and Therapeutics, 2015, 98, 321-327.	4.7	21
54	Graphic Mining of Highâ€Order Drug Interactions and Their Directional Effects on Myopathy Using Electronic Medical Records. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 481-488.	2.5	15

#	Article	IF	Citations
55	How to Choose In Vitro Systems to Predict In Vivo Drug Clearance: A System Pharmacology Perspective. BioMed Research International, 2015, 2015, 1-9.	1.9	8
56	A Mixture Doseâ€“Response Model for Identifying Highâ€Dimensional Drug Interaction Effects on Myopathy Using Electronic Medical Record Databases. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 474-480.	2.5	12
57	220: Placental metabolism does not contribute to increased clearance of nifedipine in pregnancy. American Journal of Obstetrics and Gynecology, 2015, 212, S123.	1.3	0
58	394: Fetal and maternal livers produce unique patterns of progesterone metabolites. American Journal of Obstetrics and Gynecology, 2015, 212, S205.	1.3	0
59	Fetal hyperglycemia and a high-fat diet contribute to aberrant glucose tolerance and hematopoiesis in adult rats. Pediatric Research, 2015, 77, 316-325.	2.3	7
60	Short-term tocolytics for preterm delivery – current perspectives. International Journal of Women's Health, 2014, 6, 343.	2.6	38
61	Gestational diabetes induces alterations in the function of neonatal endothelial colony-forming cells. Pediatric Research, 2014, 75, 266-272.	2.3	26
62	Is personalized medicine achievable in obstetrics?. Seminars in Perinatology, 2014, 38, 534-540.	2.5	11
63	Influence of Dietary Protein on Glomerular Filtration Before and After Bariatric Surgery: A Cohort Study. American Journal of Kidney Diseases, 2014, 63, 598-603.	1.9	14
64	Pharmacoepidemiologic and in vitro evaluation of potential drugâ€“drug interactions of sulfonylureas with fibrates and statins. British Journal of Clinical Pharmacology, 2014, 78, 639-648.	2.4	18
65	Predicting the Glomerular Filtration Rate in Bariatric Surgery Patients. American Journal of Nephrology, 2014, 39, 8-15.	3.1	77
66	An integrated pharmacokinetics ontology and corpus for text mining. BMC Bioinformatics, 2013, 14, 35.	2.6	44
67	Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. European Journal of Clinical Pharmacology, 2013, 69, 439-448.	1.9	25
68	Integration of In Vitro Binding Mechanism Into the Semiphysiologically Based Pharmacokinetic Interaction Model Between Ketoconazole and Midazolam. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-8.	2.5	3
69	Nifedipine Pharmacokinetics Are Influenced by CYP3A5 Genotype When Used as a Preterm Labor Tocolytic. American Journal of Perinatology, 2013, 30, 275-282.	1.4	38
70	CYP2B6 Pharmacogeneticsâ€“Based In Vitroâ€“In Vivo Extrapolation of Efavirenz Clearance by Physiologically Based Pharmacokinetic Modeling. Drug Metabolism and Disposition, 2013, 41, 2004-2011.	3.3	25
71	A Semiâ€Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics. CPT: Pharmacometrics and Systems Pharmacology, 2012, 1, 1-9.	2.5	22
72	A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 419-423.	1.5	21

#	Article	IF	Citations
73	Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions. PLoS Computational Biology, 2012, 8, e1002614.	3.2	104
74	Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2011, 56, 361-367.	1.5	158
75	Non-compartment model to compartment model pharmacokinetics transformation meta-analysis â€“ a multivariate nonlinear mixed model. BMC Systems Biology, 2010, 4, S8.	3.0	18
76	Measuring the Glomerular Filtration Rate in Obese Individuals without Overt Kidney Disease. Nephron Clinical Practice, 2010, 116, c224-c234.	2.3	38
77	Physiologically Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by Clarithromycin. Drug Metabolism and Disposition, 2010, 38, 241-248.	3.3	75
78	Inhibition of CYP3A by Erythromycin: In Vitro-In Vivo Correlation in Rats. Drug Metabolism and Disposition, 2010, 38, 61-72.	3.3	18
79	Independent influence of dietary protein on markers of kidney function and disease in obesity. Kidney International, 2010, 78, 693-697.	5.2	16
80	Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite. Drug Metabolism and Disposition, 2009, 37, 1587-1597.	3.3	86
81	Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. Pharmacogenomics Journal, 2009, 9, 319-326.	2.0	53
82	Literature mining on pharmacokinetics numerical data: A feasibility study. Journal of Biomedical Informatics, 2009, 42, 726-735.	4.3	16
83	A new probabilistic rule for drugâ€“dug interaction prediction. Journal of Pharmacokinetics and Pharmacodynamics, 2009, 36, 1-18.	1.8	4
84	Interaction between midazolam and clarithromycin in the elderly. British Journal of Clinical Pharmacology, 2008, 65, 98-109.	2.4	46
85	Hydroxyitraconazole, Formed During Intestinal First-Pass Metabolism of Itraconazole, Controls the Time Course of Hepatic CYP3A Inhibition and the Bioavailability of Itraconazole in Rats. Drug Metabolism and Disposition, 2008, 36, 1097-1101.	3.3	30
86	OIV-B-4Physiologically-based pharmacokinetic models for the inhibition of midazolam clearance by erythromycin and diltiazem. Clinical Pharmacology and Therapeutics, 2006, 79, P34-P34.	4.7	0
87	PIII-55Prediction of clarithromycin nonlinear pharmacokinetics and its interaction with midazolam using a physiologically-based pharmacokinetic model. Clinical Pharmacology and Therapeutics, 2006, 79, P73-P73.	4.7	0
88	Hydrolysis of Capecitabine to 5â€²-Deoxy-5-fluorocytidine by Human Carboxylesterases and Inhibition by Loperamide. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 1011-1016.	2.5	157
89	HYDROLYSIS OF IRINOTECAN AND ITS OXIDATIVE METABOLITES, 7-ETHYL-10-[4-<1>N</1>-(5-AMINOPENTANOIC) 7-ETHYL-10-[4-(1-PIPERIDINO)-1-AMINO]-CARBONYLOXYCAMPTOTHECIN, BY HUMAN CARBOXYLESTERASES CES1A1, CES2, AND A NEWLY EXPRESSED CARBOXYLESTERASE ISOENZYME, CES3. Drug Metabolism and Disposition, 2004, 32, 505-511.	3.3	121
90	Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. Clinical Cancer Research, 2003, 9, 4983-91.	7.0	96